Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination — Stella

Home/Diabetes Mellitus, Type 2/The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination

View on ClinicalTrials.gov

Recruiting

Back to Diabetes Mellitus, Type 2 trials

The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination

Trial locations(1 site)

Greece

"Attikon" University General Hospital, Athens, Attica

Key details

Sponsor

University of Athens

Enrollment target

~240 participants

Started

November 2017

Primary completion

December 2026

Age range

45 Years – 80 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.